Skip to content
Laxxon Medical

Laxxon Medical

Pipeline

As of November 2026

Laxxon develops its own Advanced Patented Generics with SPID®: established active ingredients in new oral dosage forms, for the FDA 505(b)(2) pathway in the US and the hybrid application in the EU. The lead program is LXM.2, an oral GLP-1 RA.

Focus program · LXM.2

An oral GLP-1 RA, enabled by SPID® technology

The challenge

Most GLP-1 RA medicines are peptides, and peptide medicines usually have to be injected. Peptides are large molecules that pass poorly through the gut wall and are broken down by enzymes and bacteria in the gastrointestinal tract. As a result, only a small fraction of an oral dose reaches the bloodstream (low oral bioavailability).

The approach

SPID® prints without heat, so heat-sensitive active ingredients such as peptides stay intact. SPID®-printed dosage forms are designed to protect the peptide from enzymes and bacteria on its way through the gastrointestinal tract and to release it where it can be absorbed, with the aim of improving oral bioavailability. For LXM.2, Laxxon is developing SPID®-printed oral GLP-1 RA microtablets.

The status

In preclinical development, with Phase 1 planned for 2027.

Sources: Drucker DJ, Advances in oral peptide therapeutics, Nature Reviews Drug Discovery 2020;19:277–289; company information and press release of October 21, 2026.

How SPID® works for peptides →

Disclosed programs

Six further programs are in preclinical development; details are not disclosed.

Partnering on pipeline assets

Laxxon is open to licensing and co-development partnerships for individual assets.

Contact us